🔴 GILD.BA is trading 0.1% down today as it consolidates Friday's FDA-driven gains

GILD.BA is trading 0.1% down today at $49,020, giving back a small portion of Friday’s FDA-approval rally.

• The stock surged 3.1% on June 26 after the U.S. FDA approved Gilead’s antibody-drug conjugate Trodelvy for first-line treatment of metastatic triple-negative breast cancer.
• This landmark expansion into the initial treatment setting marks a significant milestone for the company's oncology portfolio.
• Today’s minor move is characterized as normal consolidation, occurring while broader U.S. indices trade moderately higher.